Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53 172R-H ). Nonlactating, multiparous WAP-DES mice exhibited hyperplastic lesions termed mammary interepithelial neoplasia (MIN) which constitutively expressed WAP-DES. By 23 months of age, 53% of the WAP-DES mice developed mammary adenocarcinomas. A 75% reduction in both apoptosis and proliferation was observed in the normal mammary glands of WAP-DES mice. Mammary tumor incidence in WAP-DES/p53 bitransgenic mice was similar to that of WAP-DES and 2 ± 3-fold greater than that of nontransgenic and p53
Introduction
Insulin gene family members cooperate with ovarian steroids and growth hormone in stimulating normal mammary gland development (Kleinberg, 1997) . Both clinical studies and experimental models also support their roles in mammary tumorigenesis. Expression of IGF-I and -II and the IGF-I receptor (IGF-IR) has been observed in both breast cancer and the surrounding normal tissue (Cullen et al., 1990; Yee et al., 1988 Yee et al., , 1989 . In addition, expression of the IGF-IR in breast cancer has been associated with resistance to radiotherapy and increased risk of local recurrence after surgical removal of the primary tumor (Turner et al., 1997) .
Transgenic mice which overexpress IGF-II in the mammary gland exhibit an increased frequency of mammary tumors (Bates et al., 1996; Pravtcheva and Wise, 1999) . Experiments in nude mice also have demonstrated reduced growth of certain breast cancer cell lines as a result of treatment with an IGF-IR blocking antibody (Arteaga, 1992) . In addition, cells which lack IGF-IR cannot be transformed in culture by SV40 T-antigen (Sell et al., 1993) . Inactivation of p53 has been described as one of the mechanisms by which T-antigen causes tumors (Symonds et al., 1994) . Recently, transgenic mice which exhibit mammary gland-speci®c expression of a murine p53 possessing an arginine to histidine substitution at codon 172 (p53 172R-H ) have been characterized (Li et al., 1998) . The murine 172
R-H mutation is analogous to a missense mutation (p53 175 R-H ) that is frequently observed in human breast cancer (Hainaut et al., 1997) and has been associated with a poor prognosis (Aas et al., 1996) . The p53 175 R-H protein is a dominant-negative mutant in that it can interact with wildtype p53, but is no longer capable of speci®c DNA binding (Kern et al., 1992; Ory et al., 1994) . However, it also appears to confer a variety of novel functions (Gualberto et al., 1998; Dittmer et al., 1993) indicating that it is also a gain-of-function p53 mutant. The p53
172R-H mice develop few spontaneous mammary tumors. However, susceptibility to mammary tumorigenesis is markedly increased in p53
172R-H mice following treatment with the carcinogen DMBA (Li et al., 1998) or with coexpression of oncogenes such as neu (Li et al., 1997) . This supports the suggestion that this gain-of-function mutant is capable of cooperating with a number of dierent factors known to in¯uence mammary tumorigenesis.
Cooperation between IGF-I and mutant p53 enables cultured cells to grow in the absence of serum (Gai et al., 1988) . In addition, p53 has been shown to regulate the expression of IGFBP3, IGF-IR and insulin receptor in cell culture (Buckbinder et al., 1995; Werner et al., 1996; Webster et al., 1996) . This suggests that there is a p53/IGF axis, whereby increases in wildtype p53 by DNA damage may induce apoptosis in part by down-regulating the antiapoptotic eects of IGF-I.
The ability of overexpressed IGF-I to cause mammary tumors, however, has not been reported to date. Previous studies (Hadsell et al., 1996) in our laboratory have shown that lactation-dependent, mammary-speci®c overexpression of a potent IGF-I analog with reduced anity for IGF binding proteins, des(1-3)hIGF-I (WAP-DES), inhibits normal mammary gland involution. At the time of that study, a small number of WAP-DES mice had been observed to develop palpable mammary tumors. The goals of the present study were, therefore, (1) to characterize in detail the mammary tumor incidence and latency in the WAP-DES mice, (2) to study the role of the p53/IGF axis in mammary tumorigenesis using a bitransgenic mouse model carrying both WAP-DES and p53 172R-H , and (3) to examine potential mechanisms by which the cooperation between WAP-DES and p53
172R-H might occur.
Results

Mammary tumorigenesis in the WAP-DES mice
To characterize in detail the mammary tumor incidence and latency in the WAP-DES mice, cohorts of WAP-DES and nontransgenic mice were examined weekly for palpable tumors. By the end of the study the mice had undergone from one to ®ve (2.8+0.3, mean +s.e.m.) lactations and were 13 ± 25 (20+1.1) months old. Of the 15 WAP-DES mice in the study, two died due to causes unrelated to mammary tumors and eight (53%) developed palpable mammary tumors ( Figure  1d ) by 23 months of age. The average tumor latency was 20+6 months. Of these, two mice developed more than one tumor. Of the nine tumors analysed, seven displayed a pathology ( Figure 1a ) consistent with the classi®cation of adenocarcinoma type B (Dunn, 1959) . In most cases mitotic ®gures were present ( Figure 1a ) and most of the tumors contained regions of keratinization and central necrosis ( Figure 1c ). One tumor displayed pathology consistent with a squamous adenocarcinoma (Figure 1c) , and another that of a papillary adenocarcinoma (Figure 1b) . No tumors were detected in the nontransgenic littermates.
Histological analysis of the mammary tissues of these non-lactating WAP-DES mice demonstrated a variety of morphological abnormalities (Figure 2 ) that were absent in the nonlactating nontransgenic littermates. Of the six nontransgenic mice analysed, all displayed normal ductal and lobulo-alveolar development similar to that shown in Figure 2a . Of the 13 WAP-DES mice analysed, eight (62%) had microadenomas ( Figure 2c) . All of the WAP-DES mice demonstrated either low grade (Figure 2b ) or high grade mammary interepithelial neoplasia (MIN) as recently de®ned by an NIH-sponsored meeting on the pathology of genetically engineered mice (Cardi et al., 2000) . Of the mice bearing palpable tumors, all exhibited MIN lesions similar to those in Figure 2 .
Immunostaining for hIGF-I revealed aberrant, lactation-independent, transgene expression within the (Figure 3d ) MIN. Human IGF-I expression was also detected by immunohistochemistry in ®ve out of seven tumors analysed (data not shown). Staining of mammary tissue sections from WAP-DES mice at 15 days of lactation revealed abundant luminal hIGF-I (Figure 3b ). This was not observed in nontransgenic mice at the same stage of lactation ( Figure 3a ) nor was it detected in nonlactating, multiparous, nontransgenic mice at 13 ± 25 months of age (Figure 3c ).
Apoptosis and DNA synthesis in the WAP-DES mice
The presence of mammary tumors and hyperplasias, coupled with our previous observation (Hadsell et al., 1996) of inhibited mammary involution in the WAP-DES mice, led us to examine the eects of WAP-DES expression on apoptosis and DNA synthesis in the mammary gland. The mammary gland gradually begins to involute between days 15 and 22 of lactation (Quarrie et al., 1996) . This natural involution depends on apoptosis and displays many of the hallmarks that have been observed with forced involution (Strange et al., 1992) . To test whether des(1-3)hIGF-I inhibits the apoptosis that occurs during natural involution, TUNEL analysis was conducted on mammary glands from 20-day lactating primiparous nontransgenic and WAP-DES mice. BrdU incorporation was measured to determine if DNA synthesis was also altered. TUNEL analysis of mammary glands from a 15-day lactating mouse served as a negative control and revealed few labeled nuclei (Figure 4a ). A similar result was obtained for BrdU labeling of 15-day lactating mammary tissue (data not shown). Mammary tissue from nontransgenic mice at 20 days of lactation contained an increased number of both apoptotic ( Figure 4b ) and BrdU-labeled (Figure 4c ) cells. Mammary tissue from nontransgenic mice at day 20 of lactation contained 3.7+0.6% and 3.7+0.8% apoptotic and BrdU-labeled cells, respectively ( Figure  4d ). By comparison, WAP-DES mice at the same day of lactation (Figure 4d ) had 75% fewer (P50.05) apoptotic cells (0.9+0.3%) and 68% fewer (P50.05) BrdU-labeled cells (1.2+0.5). These results are consistent with the earlier hypothesis that decreased apoptosis was responsible for the previously observed inhibition of mammary involution in the WAP-DES mice.
Cooperation between IGF-I and p53 in mammary tumorigenesis
Evidence from cell culture studies (Gai et al., 1988; Webster et al., 1996; Buckbinder et al., 1995; Werner et al., 1996) supports the idea that mutant forms of p53 may interact with the IGF signaling pathway to enhance cell proliferation, survival, or transformation. To determine if this interaction is capable of increasing the mammary tumor incidence in mice, a previously characterized (Li et al., 1998) line of transgenic mice which overexpresses a mutant form of p53 containing an arginine to histidine substitution at codon 172 (p53 172R-H ) was crossed with the WAP-DES mice. The incidence of palpable mammary tumors was 2.8-and 3-fold higher (P50.005) in WAP-DES and bitransgenic mice, respectively, than in nontransgenic mice (Table 1 ). In addition, the incidence of mammary tumors in p53
172R-H mice was not signi®cantly greater than that of nontransgenic mice. Analysis of tumor pathology in hematoxylin-eosin-stained sections demonstrated that a majority of the tumors were what has been previously described as adenocarcinoma type B (Dunn, 1959) . Tumors from the p53 172R-H mice. The mean tumor-free survival time was 14+1, 22+2, 22+1, and 24+2 months for bitransgenic, WAP-DES, p53 172R-H , and nontransgenic mice, respectively. These data support the conclusion that des(1-3)hIGF-I and p53
172R-H act synergistically to reduce mammary tumor latency. 
Mechanism of synergy
Previous studies (Li et al., 1998; Wang et al., 1998) have demonstrated aneuploidy in both mammary and skin tumors occurring in DMBA-treated mice carrying a targeted p53
172R-H transgene. To determine if p53
172R-H expression results in a predisposition to aneuploidy in the context of the WAP-DES transgene, FACS analysis was conducted on tumor cell nuclei. Half of the tumors from p53 172R-H and bitransgenic mice were aneuploid (Table 1 ). Relatively few aneuploid tumors did eventually arise in WAP-DES and nontransgenic control mice. However, as discussed above, these tumors appeared much later than the aneuploid tumors arising in the bitransgenic mice, and the aneuploidy in those cases could have been the result of stochastic late genetic alterations. Increased genomic instability in tumors arising in the bitransgenic mice appears to result from overexpression of this gain-of-function p53 mutant, and is not in¯uenced by overexpression of des(1-3)hIGF-I. The ability of this mutant p53 protein to promote genomic instability is likely an important part of the synergy between WAP-DES and p53 172R-H . To determine if reduced tumor latency in the bitransgenic mice was associated with changes in mammary cell proliferation or apoptosis, these parameters were measured in both the end-stage tumors (Figure 6c R-H or nontransgenic mice. An average of 1.2+0.5% apoptosis was observed in this mammary tissue (Figure 6d ). Apoptosis was not in¯uenced by genotype. In contrast, Ki67 staining in the MIN from WAP-DES mice was 3 ± 9-fold higher (P50.04) than that observed in mammary tissue obtained from mice of the other three genotypes (Figure 6d) . Thus, early decreases in apoptosis ( Figure  4 ) coupled with later increases in proliferative capacity are associated with the occurrence of MIN and the eventual appearance of tumors in the mammary glands of WAP-DES mice. However, the ability of p53 to reduce tumor latency in the WAP-DES mice does not In addition to the eects of p53 172R-H on genomic instability, the potential exists for this mutant to act as a dominant-negative to repress genes that would normally be transcriptionally activated by wildtype p53 (Hachiya et al., 1994) . The observation that wildtype p53 can induce the transcription of IGFBP3 and repress the expression of the IGF-I receptor in cell culture is of particular interest because it suggests that there is an IGF/p53 axis. Activation of this axis in the presence of wildtype p53 by DNA damage may induce apoptosis in part by down-regulating the antiapoptotic eects of IGF-I. The dominant negative properties of the p53
172R-H mutant should abrogate this axis and potentially increase the sensitivity of cells to insulin-like signals.
To determine if p53 172R-H expression could in¯uence the expression of IGFBP3 and IGF-IR, ribonuclease protection assays were conducted using subcloned fragments of mouse IGFBP3 and IGF-IR cDNAs. These results, summarized in Figure 7a for IGFBP3 and Figure 7b for IGF-IR, demonstrated that tumors derived from WAP-DES mice expressed 2 ± 3-fold (P50.02) more IGFBP3 than that found in nontransgenic, p53 172R-H , and bitransgenic mice (Figure 7c ). The expression of the IGF-IR mRNA was similar among all four tumor genotypes. Thus, as expected, expression of the p53
175R-H mutant interfered with the ability of WAP-DES to induce IGFBP3 expression.
Discussion
Tumorigenesis in the WAP-DES mice
This study demonstrates the direct involvement of IGF-I in mouse mammary gland tumorigenesis. Disruption of normal interactions between p53 and IGF-mediated signaling pathways can also accelerate mammary tumorigenesis. Mammary adenocarcinomas have been observed in transgenic mice as a result of IGF-II overexpression under control of either the blactoglobulin (bLG) promoter (Bates et al., 1996) or the H19 enhancer region (Pravtcheva and Wise, 1999) . As with the results obtained with the WAP-DES mice, the tumors that result from IGF-II overexpression occur with a fairly long latency.
The mechanism underlying the appearance of mammary tumors in the IGF transgenic models is speculative at present. Previous results demonstrated that mammary involution was inhibited in the WAP-DES mice (Hadsell et al., 1996) . In addition, inhibition of apoptosis has been demonstrated in transgenic mice which overexpress wildtype IGF-I in the mammary gland (Neuenschwander et al., 1996) . Consequently, the inhibition of apoptosis observed in the mammary gland following overexpression of des(1-3)hIGF-I was not unexpected. The decrease observed in DNA synthesis in the mammary glands of WAP-DES mice probably re¯ects the fact that entry into S phase is often a prerequisite for programmed cell death (Neiman et al., 1994) . This is also consistent with the observed decrease in apoptosis. Previous studies in mice which overexpress T-antigen in the pancreas have demonstrated that IGF-II-dependent inhibition of apoptosis is a critical factor in tumorigenesis in that model (Christofori et al., 1994) . Decreased apoptosis has also been associated with the ability of TGF-a to cause mammary tumors (Amundadottir et al., 1996) . Thus, reduced apoptosis 172R-H (&), and bitransgenic (*) mice, respectively. Symbols represent censored animals. Animals which either died for reasons other than mammary tumors or were euthanized at the end of the study were censored. Overall tumor frequency was 4/14, 8/10, 6/ 14, and 17/19 for nontransgenic, WAP-DES, p53 172R-H , and bitransgenic mice, respectively. Tumor latency was signi®cantly decreased in bitransgenic mice (P50.0001). Arrow shows mitoses. Magni®cation is 4006 is likely an important factor in tumorigenesis in the WAP-DES mice.
The mechanism of cooperation between WAP-DES and p53
172R-H
In all of the p53 172R-H models analysed to date, a common feature is the dramatically altered nuclear morphology and high degree of aneuploidy observed in the resulting tumors (Murphy and Rosen, 2000).
Tumors from both humans and rodents frequently show both loss of heterozygosity and mutation of the remaining p53 allele (Hollstein et al., 1991; Ben-David and Berstein, 1991) . This is associated with defective cell cycle arrest and genomic instability (Livingstone et al., 1992) . Genomic instability may be related in part to abnormal centrosome ampli®cation (Fukasawa et al., 1996) , as well as defects in DNA repair (Morgan et al., 1998) . Abnormal centrosome ampli®cation in skin carcinogenesis has been described in transgenic mice , and bitransgenic mice. TUNEL staining for apoptosis ( ) was measured as described in Figure 1 . Expression of the S phase marker Ki 67 ( ) was used to estimate cell cycle progression. Paran sections were stained with rabbit anti human Ki 67 (Novocastra Laboratories) at 1 : 4000 dilution and then counterstained with Meyer's hematoxylin. Examples of staining in tumors from either WAP-DES (a) or p53
172R-H (b) mice show that this marker is detected in both interphase nuclei and in mitoses. Staining varied from faint to very intense (arrows in a). Both faint and intensely stained nuclei were pooled for quantitation purposes. Quantitation of Ki 67 positive cells was conducted as described in 172R-H under the control of the human keratin 1 promoter (Wang et al., 1998) . These eects appear to be due to the gain of function properties of this p53 mutant and may be independent of direct eects of p53 on gene transcription (Gualberto et al., 1999) . Thus, the predisposition to development of genomic instability conferred by this p53 mutant is probably the major mechanism by which p53
172R-H cooperates with IGF-I in mammary tumorigenesis. Genomic instability coupled with the antiapoptotic and proliferative eects of WAP-DES may provide an early target cell population with a selective growth advantage, facilitating the more rapid appearance of palpable tumors.
The observed elevation of IGFBP3 mRNA in the WAP-DES tumors is consistent with cell culture models which have shown increased IGFBP3 mRNA in response to treatment with exogenous IGF-I (Conover and Bale, 1992; Villafuerte et al., 1996) . This elevation was not observed in tumors from bitransgenic mice, suggesting that the dominant negative properties of the p53 175R-H mutant may interfere with the induction of IGFBP3 mRNA by WAP-DES. Transcription of the IGFBP3 gene has been shown to be increased by direct interaction of wildtype p53 with consensus p53 DNA binding sites within the IGFBP3 promoter (Buckbinder et al., 1995) . The eects of IGFBP3 on cells in culture have been attributed to both IGF-IR-dependent and -independent mechanisms (Valentinis et al., 1995; Conover and Powell, 1991) . Exposure of human breast cancer cells in culture to IGFBP3 has been shown to inhibit growth and predispose the cells toward ceramide-induced apoptosis (Gill et al., 1997) . These actions appear to occur through a IGF-IR-independent mechanism. Because des(1-3)IGF-I has reduced anity for IGFBP3, the potential eects of altered IGFBP3 expression in WAP-DES or bitransgenic mice would have to occur through the IGF-IR-independent 172R-H (lanes 8, 13), and bitransgenic (lanes 3 ± 6 and 11) mice. Yeast RNA controls are in lanes 1, 2, 9, and 10. Undigested probes were run in lanes 1 and 10. Cyclophilin mRNA (CYC) was used as a loading control. The sizes of the protected fragments were 302, 332 and 103 nt for IGF-IR, IGFBP3 and cyclophilin, respectively. Quantitation of IGF-IR ( ) or IGFBP-3 ( ) mRNA abundance (c). The abundance of IGFBP3 mRNA was 2 ± 2.5-fold greater in WAP-DES compared to nontransgenic, p53
172R-H or bitransgenic mice (*P50.02). Sample numbers are shown in parentheses mechanism as well. Regardless, the inhibition of the WAP-DES-dependent induction of IGFBP3 mRNA, supports the hypothesis that p53
175R-H may also in¯uence tumorigenesis by in¯uencing expression of growth regulators such as IGFBP3.
The absence of an eect of p53 172R-H on the IGF-IR mRNA may be related to the indirect, rather than direct mechanism employed by p53 to regulate IGF-IR gene transcription. In cell culture studies, wildtype p53 has been reported to repress IGF-IR expression indirectly through interactions with TBP (Werner et al., 1996) and SP1 (Ohlsson et al., 1998) . However, based on the results of our studies, the signi®cance of these observations in vivo is questionable.
In conclusion, cooperative interactions between IGF signaling pathways and p53
172R-H dramatically increase mammary tumorigenesis. This eect is likely due to an early selective event that involves both predisposition to genomic instability and alterations in the transcription of p53-regulated genes.
Materials and methods
Tumorigenesis
The mice used in the initial tumorigenesis study and the study on mammary apoptosis were from a previously characterized (Hadsell et al., 1996) line (8266) which overexpresses des(1-3)hIGF-I within the mammary gland under the control of the rat WAP promoter (WAP-DES). Their genetic background was ICR6B6C3F1. During the course of characterizing the line, two females were observed to develop palpable mammary adenocarcinomas. To pursue this initial observation, the remaining animals in that study were followed to an age range of 13 to 25 months. At the end of the study, mammary tissue and tumor samples were collected from all animals regardless of tumor status. The resulting cohort of nontransgenic (n=6) and WAP-DES mice (n=15) had completed from two to ®ve lactations and ranged in age from 13 to 25 months. Within 1 week after the appearance of a palpable tumor, each animal was euthanized and tissues were collected.
In the bitransgenic tumorigenesis study, bitransgenic males were produced by crossing mice from the WAP-DES line with mice carrying p53 172R-H . The genetic background of the p53 172R-H mice was FVB. Potential variation due to genetic background was controlled by studying the siblings which resulted from the mating of bitransgenic males (ICR6B6C3F16FVB) to nontransgenic females (B6C3F1). Female ospring which were nontransgenic (n=14), WAP-DES (n=10), p53
172R-H (n=14), or bitransgenic (n=19) were then housed continuously with a male and followed for the appearance of mammary tumors. The average age and parity of animals in each genotype is listed in Table 1 . Within 1 week after the appearance of a palpable tumor, each animal was euthanized and tissues were collected for histological analysis. At the termination of the study, all animals were euthanized regardless of tumor status and tissues were collected.
Apoptosis and proliferation in the WAP-DES mice
The eects of WAP-DES expression on apoptosis and cell proliferation in the normal mammary gland were analysed. To accomplish this, WAP-DES (n=3) and nontransgenic mice (n=3) were allowed to complete a normal pregnancy. At day 2 of lactation, the litter size was normalized to ten pups/litter. On day 20, the dams were injected with BrdU in sterile saline at 80 mg/kg BW. After a 2-h labeling period, the animals were euthanized and tissues were collected.
Histology
Tissue was ®xed and processed for immunohistochemistry (Hadsell et al., 1996) . Mammary tissue sections were stained for apoptosis or BrdU incorporation using previously described procedures (Li et al., 1997 (Li et al., , 1998 . Labeling index was obtained by counting labeled and unlabeled epithelial cells in 8 ± 12 (about 1000 cells total) ®elds at 10006 magni®cation.
Mammary tissue and tumor sections were stained for human IGF-I with the monoclonal antibody 82-9a (Oncogene Science, Manhasset, NY, USA). Following rehydration into PBS, the sections were incubated in TUF as described above. Following the antigen recovery step, the sections were incubated in PBS containing 10% normal sheep serum and 10% sheep anti-mouse IgG1 (The Binding Site, Birmingham, UK). The sections were incubated in PBS with 10% normal sheep serum and a 1 : 100 dilution of primary anti-hIGF-I overnight at room temperature. The sections were then washed with PBS containing 0.1% Tween 20 (PBST) and incubated for 10 min at room temperature in PBS containing 0.1% sodium azide (Sigma Chemical Company, St Louis, MO, USA) and 0.3% hydrogen peroxide. After the peroxide blocking step, sections were washed in PBST and incubated for 30 min at 408C in PBS containing biotin-conjugated sheep anti mouse IgG1 at a 1 : 500 dilution. Following the second antibody incubation, the sections were washed in PBST and the biotin-conjugate antibody complex was detected as described above. Sections were counterstained with 0.1% aqueous methylene green and mounted for microscopy.
Sections of tumors or MIN were stained for Ki67 to estimate the number of cells in the S/G2/M phases of the cell cycle. The antigen retrieval step consisted of boiling the sections in 0.01 M citrate buer (pH 6.0) for 1 min under a pressure of 86 Kpa. The sections were then blocked for 10 min at 408C in PBS with 10% normal goat serum and 0.1% sodium azide. Following the blocking step, the sections were incubated overnight at room temperature in a 1 : 4000 dilution of rabbit anti human Ki67 (Nova Castra Laboratories, Burlingame, CA, USA) in PBS with 10% normal goat serum and 0.1% sodium azide. The sections were then incubated with biotin-conjugated goat anti rabbit at a 1 : 1000 dilution as described above. Following detection of the biotin-conjugate antibody complex, the sections were counterstained for 2.5 min with Meyer's hematoxylin solution (Sigma Chemical Corp, St. Louis, MO, USA) and mounted for microscopy. The percentage of positive cells was estimated as described above for apoptosis analysis.
Flow cytometry analysis
Flow cytometry analysis of paran-®xed tumor samples was performed as previously described (Li et al., 1998) . The number of observations per genotype were 4, 12, 7, and 15 for nontransgenic, WAP-DES, p53
172R-H and bitransgenic tumors, respectively.
RNA analysis
The abundance of IGFBP3 and IGF-I receptor mRNAs was measured using speci®c antisense riboprobes. The plasmid pa603 served as a template for the mouse IGF-I receptor riboprobe. This plasmid was produced by ligating a 302 bp RsaI fragment (nt 603 ± 901) derived from the mouse IGF-I receptor cDNA (Wada et al., 1993) into the HincII site of bluescript SK (+). The plasmid pBP3332 served as a template for mouse IGFBP3 riboprobe. This plasmid was produced by ligating a 332 bp EcoRI/MluI fragment (nt 1 ± 332) derived from the mouse IGFBP3 cDNA (Schuller et al., 1994) into the EcoRI and HincII sites of Bluescript SK (+) (Stratagene, La Jolla, CA, USA). Templates for antisense probes were prepared by digesting the plasmids with EcoRI. The resulting digests were then treated for 30 min with proteinase K (1 mg/ml), extracted with phenol and phenol:-chloroform, and then concentrated by ethanol precipitation. The pTRI-cyclophilin-mouse antisense control template (Ambion Inc., Austin, TX, USA) was used to measure cyclophilin mRNA as a loading control. Templates were used to make 32 P-labeled riboprobes by in vitro transcription using the Promega Riboprobe Combination T7/T3 system (Promega Corp., Madison, WI, USA). Gel-puri®ed riboprobes were then used in RPA assays performed with the RPA II kit from Ambion (Ambion Inc., Austin, TX, USA). Transcripts of 362 and 363 nt were obtained for pa603 and pBP3332, respectively (Figure 7, lanes 1 and 10) . Transcripts of 138 or 165 nt were obtained for pTRI-cyclophilin transcribed with T3 or T7 polymerase, respectively. Hybridization reactions conducted with mammary tumor RNA produced major protected fragments of 302, 332, and 103 nt for IGTF-IR, IGFBP3 and cyclophilin, respectively. Hybridization reactions conducted with yeast RNA failed to result in RNAse-protected fragments ( Figure 7 , lanes 2 and 9).
Statistical analysis
Tumor-free probability was estimated using the KaplanMeier analysis (SPSS). Dierences in the survival curves were considered signi®cant at P50.05. Dierences in the tumor incidence and aneuploidy were tested by w 2 . All other data were analysed using a one-way analysis of variance (Minitab) with four genotypes. Dierences were considered signi®cant at P50.05.
